Histologic muscular history in steroid-treated and untreated patients with Duchenne dystrophy

被引:49
作者
Peverelli, Lorenzo [1 ]
Testolin, Silvia [1 ]
Villa, Luisa [1 ]
D'Amico, Adele
Petrini, Stefania [2 ]
Favero, Chiara [4 ]
Magri, Francesca [5 ]
Morandi, Lucia [6 ]
Mora, Marina [6 ]
Mongini, Tiziana [7 ]
Bertini, Enrico [3 ]
Sciacco, Monica [1 ]
Comi, Giacomo P. [5 ]
Moggio, Maurizio [1 ]
机构
[1] Fdn IRCCS Ca Granda, Osped Maggiore Policlin, Neuromuscular & Rare Dis Unit, Dept Neurosci, Milan, Italy
[2] Confocal Microscopy Facil, Res Ctr, Lab Mol Med Muscular & Neurodegenerat Dis, Rome, Italy
[3] Bambino Gesu Pediat Hosp, Unit Neuromuscular & Neurodegenerat Disorders, Dept Neurosci, Rome, Italy
[4] Univ Milan, Ctr Mol & Genet Epidemiol, Dept Clin Sci & Community Hlth, Milan, Italy
[5] Univ Milan, IRCCS Fdn Ca Granda, Dino Ferrari Ctr,Dept Pathophysiol & Transplantat, Neurosci Sect,Neurol Unit,Osped Maggiore Policlin, Milan, Italy
[6] Fdn IRCCS Ist Neurol C Besta, UO Neuromuscular Dis & Neuroimmunol, Milan, Italy
[7] Univ Turin, Dept Neurosci Rita Levi Montalcini, I-10124 Turin, Italy
关键词
MUSCLE REGENERATION; EPIGENETIC CONTROL; POSITIVE FIBERS; NATURAL-HISTORY; ACTIVATION; TRIAL; DMD;
D O I
10.1212/WNL.0000000000002147
中图分类号
R74 [神经病学与精神病学];
学科分类号
100204 [神经病学];
摘要
Objective:Duchenne muscular dystrophy (DMD) is a lethal disease. The outcome measures used in numerous therapeutic trials include skeletal muscle biopsy. We studied the natural history of DMD from the standpoint of muscle histology with the aim of providing a reproducible tool for use in evaluating and comparing any histologic changes occurring in patients with DMD undergoing treatment and hence be able to determine how therapy modulates the histologic evolution of the disease.Methods:Three independent operators analyzed 56 muscle biopsies from 40 patients not treated with steroids, aged 1 to 10 years and 16 individuals treated with steroids, aged 7 to 10 years. We analyzed morphologic measures, normalized every measure for the average number of fibers observed for each year of age, and calculated intraclass correlation coefficients.Results:The average proportion of connective tissue in patients not treated with steroids was 16.98% from ages 1 to 6 years and 30% from ages 7 to 10 years (p < 0.0001). The average proportion in patients treated with steroids was 24.90%. Muscle fiber area mirrored that of connective tissue in both groups.Conclusions:Having provided a reproducible tool for evaluation and comparison of histologic changes occurring in patients undergoing clinical trials, it was observed that at ages 6 to 7 years, fibrotic tissue rapidly peaks to 29.85%; this is a crucial moment when muscle tissue loses its self-regeneration ability, veering toward fibrotic degeneration. These data should be considered when deciding the most suitable time to begin therapy.
引用
收藏
页码:1886 / 1893
页数:8
相关论文
共 35 条
[1]
Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: Implication for clinical trials [J].
Arechavala-Gomeza, Virginia ;
Kinali, Maria ;
Feng, Lucy ;
Guglieri, Michela ;
Edge, Geraldine ;
Main, Marion ;
Hunt, David ;
Lehovsky, Jan ;
Straub, Volker ;
Bushby, Kate ;
Sewry, Caroline A. ;
Morgan, Jennifer E. ;
Muntoni, Francesco .
NEUROMUSCULAR DISORDERS, 2010, 20 (05) :295-301
[2]
HISTOPATHOLOGICAL CHANGES IN DUCHENNE MUSCULAR DYSTROPHY [J].
BELL, CD ;
CONEN, PE .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1968, 7 (03) :529-&
[3]
Bharathy Narendra, 2013, Subcell Biochem, V61, P139, DOI 10.1007/978-94-007-4525-4_7
[4]
Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade [J].
Biggar, WD ;
Harris, VA ;
Eliasoph, L ;
Alman, B .
NEUROMUSCULAR DISORDERS, 2006, 16 (04) :249-255
[5]
Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: Results from a 12 month, double-blind, randomized placebo-controlled trial [J].
Buyse, Gunnar M. ;
Goemans, Nathalie ;
van den Hauwe, Marleen ;
Thijs, Daisy ;
de Groot, Imelda J. M. ;
Schara, Ulrike ;
Ceulemans, Berten ;
Meier, Thomas ;
Mertens, Luc .
NEUROMUSCULAR DISORDERS, 2011, 21 (06) :396-405
[6]
Long-term blinded placebo-controlled study of SNT-MC17/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance [J].
Buyse, Gunnar M. ;
Van der Mieren, Gerry ;
Erb, Michael ;
D'hooge, Jan ;
Herijgers, Paul ;
Verbeken, Erik ;
Jara, Alejandro ;
Van Den Bergh, An ;
Mertens, Luc ;
Courdier-Fruh, Isabelle ;
Barzaghi, Patrizia ;
Meier, Thomas .
EUROPEAN HEART JOURNAL, 2009, 30 (01) :116-124
[7]
Endomysial Fibrosis in Duchenne Muscular Dystrophy: A Marker of Poor Outcome Associated With Macrophage Alternative Activation [J].
Desguerre, Isabelle ;
Mayer, Michelle ;
Leturcq, France ;
Barbet, Jacques-Patrick ;
Gherardi, Romain K. ;
Christov, Christo .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2009, 68 (07) :762-773
[8]
Epigenetic regulation of satellite cell activation during muscle regeneration [J].
Dilworth, F. Jeffrey ;
Blais, Alexandre .
STEM CELL RESEARCH & THERAPY, 2011, 2
[9]
Dubowitz V., 2007, Muscle Biopsy: A Practical Approach
[10]
SHORT STATURE - A COMMON FEATURE IN DUCHENNE MUSCULAR-DYSTROPHY [J].
EIHOLZER, U ;
BOLTSHAUSER, E ;
FREY, D ;
MOLINARI, L ;
ZACHMANN, M .
EUROPEAN JOURNAL OF PEDIATRICS, 1988, 147 (06) :602-605